AL amyloidosis presenting as inflammatory polyarthritis: a case report

References

• Duna GF, Cash JM. Rheumatic manifestations of dysproteinemias and lymphoproliferative disorders. Rheum Dis Clin North Am. 1996;22(1):39–51.
   Web of Science ®Google Scholar
• Desport E, Bridoux F, Sirac C, et al. AL Amyloidosis. Orphanet J Rare Dis. 2012;7:54.
   PubMed Web of Science ®Google Scholar
• Glenne G. Amyloid deposits and amyloidosis: the beta-fibrilloses (first ot two parts). N Engl J Med. 1980;302:1283–1292.
   Google Scholar
• Wiernik PH. Amyloid joint disease. Medicine (Baltimore). 1972;51(6):465–479.
   Web of Science ®Google Scholar
• Katoh N, Tazawa KI, Ishii W, et al. Systemic AL amyloidosis mimicking rheumatoid arthritis. Intern Med. 2008;47(12):1133–1138.
   Web of Science ®Google Scholar
• Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. J Med Case Rep. 2013;7:223.
   PubMedGoogle Scholar
• Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus on AL Amyloidosis: Diagnosis and Treatment (v6, Feb 2017). [accessed 2020 Feb 19]. Available from: https://www.msmart.org/treating-al.
   Google Scholar
• Alpay N, Artim-Esen B, KamalI S, et al. Amyloid arthropathy mimicking seronegative rheumatoid arthritis in multiple myeloma: case reports and review of the literature. Amyloid. 2009;16(4):226–231.
   PubMed Web of Science ®Google Scholar
• Schoninger S, Homsi Y, Kreps A, et al. A case of multiple myeloma misdiagnosed as seronegative rheumatoid arthritis and review of relevant literature. Case Rep Rheumatol. 2018;2018:9746241.
   Google Scholar
• Prokaeva T, Spencer B, Kaut M, et al. Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival. Arthritis Rheum. 2007;56(11):3858–3868.
   PubMed Web of Science ®Google Scholar
• Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med. 2004;255(2):159–178.
   PubMed Web of Science ®Google Scholar
• Mahmood S, Palladini G, Sanchorawala V, et al. Update on treatment of light chain amyloidosis. haematologica. 2014;99(2):209–221.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48–e548.
   PubMed Web of Science ®Google Scholar
• Brambilla F, Lavatelli F, Di Silvestre D, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood. 2012;119(8):1844–1847.
   PubMed Web of Science ®Google Scholar
• Gorevic P. ‘Overview of amyloidosis.’ UpTodate; 2020 [accessed 2020 Jan 23]. Available from: https://www.uptodate.com/contents/overview-of-amyloidosis
   Google Scholar
• Sipe JD, Benson MD, Buxbaum JN, et al. Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014;21(4):221–224.
   PubMed Web of Science ®Google Scholar
• McCausland KL, White MK, Guthrie SD, et al. Light chain (AL) amyloidosis: the journey to diagnosis. Patient. 2018;11(2):207–216.
   PubMedGoogle Scholar
• Röcken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch. 2002;440(2):111–122.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol. 2005;79(4):319–328.
   PubMed Web of Science ®Google Scholar
• Gertz MA. Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid. 2010;17:48–49.
   Web of Science ®Google Scholar
• Cho YJ, Chun YS, Rhyu KH, et al. Amyloid arthropathy of the hip joint associated with multiple myeloma: a case report. Hip Pelvis. 2016;28(2):127–131.
   Google Scholar
• Vitali C, Baglioni P, Vivaldi I, et al. Erosive arthritis in monoclonal gammopathy of uncertain significance: report of four cases. Arthritis Rheum. 1991;34(12):1600–1605.
   Google Scholar
• Katz GA, Peter JB, Pearson CM, et al. The shoulder-pad sign-a diagnostic feature of amyloid arthropathy. N Engl J Med. 1973;288(7):354–355.
   Web of Science ®Google Scholar
• Cardinal E, Buckwalter KA, Braunstein EM, et al. Amyloidosis of the shoulder in patients on chronic hemodialysis: sonographic findings. AJR Am J Roentgenol. 1996;166(1):153–156.
   Web of Science ®Google Scholar
• Pepys MB. Amyloidosis. Annu Rev Med. 2006;57:223–241.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A. ‘Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis’. UpTodate; 2020 [accessed 2020 Mar 23]. Available from: https://www.uptodate.com/contents/clinical-presentation-laboratory-manifestations-and-diagnosis-of-immunoglobulin-light-chain-al-amyloidosis.
   Google Scholar
• Palladini G, Merlini G. Current treatment of AL amyloidosis. Haematologica. 2009;94(8):1044–1048.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Hawkins PN, Gillmore JD. Perspectives in treatment of AL amyloidosis. Br J Haematol. 2008;140(4):365–377.
   Web of Science ®Google Scholar
• Falck HM, Törnroth T, Wegelius O. Predominantly vascular amyloid deposition in the kidney in patients with minimal or no proteinuria. Clin Nephrol. 1983;19(3):137–142. Mar
   Web of Science ®Google Scholar
• ‘Bortezomib: Drug information’. Uptodate. [Accessed 2020 Mar 24]. Available from: https://www.uptodate.com/contents/bortezomib-drug-information.
   Google Scholar
• Yood RA, Skinner M, Rubinow A, Talarico L, et al. Bleeding manifestations in 100 patients with amyloidosis. JAMA. 1983;249(10):1322–1324.
   Web of Science ®Google Scholar
• Mumford AD, O'Donnell J, Gillmore JD, et al. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol. 2000;110(2):454–460.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Leleu X, Arnulf B, et al. Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol. 2020;38(28):JCO2001285.
   Web of Science ®Google Scholar
• Dispenzieri A. Treatment and prognosis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases. UpTodate; 2020 [accessed 2020 Aug 23]. Available from: https://www.uptodate.com/contents/treatment-and-prognosis-of-immunoglobulin-light-chain-al-amyloidosis-and-light-and-heavy-chain-deposition-diseases.
   Google Scholar
• Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336(17):1202–1207.
   PubMed Web of Science ®Google Scholar